Long-term survival among colorectal cancer patients in Finland, 1991-2015: a nationwide population-based registry study

• Published in: BMC cancer 2022-04, Vol.22 (1), p.356-356, Article 356
• Main Authors: Olenius, Tobias, Koskenvuo, Laura, Koskensalo, Selja, Lepistö, Anna, Böckelman, Camilla
• Format: Article
• Language: English
• Subjects: Age; Classification; Colon cancer; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - diagnosis; Colorectal Neoplasms - epidemiology; Colorectal Neoplasms - therapy; Disease; Finland; Finland - epidemiology; Forecasts and trends; Gender; Humans; Lymph nodes; Lymphatic system; Metastases; Metastasis; Mortality; National registry study; Patient outcomes; Population; Population studies; Population-based studies; Prognosis; Registries; Survival; Survival Rate; Tumors; Womens health
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-022-09460-0

Colorectal cancer (CRC) incidence in Finland has risen steadily. Given development in cancer treatments in recent decades, disease-specific data on the long-term prognosis of patients may be obsolete. Thus, this study aimed to report 5-year disease-specific survival (DSS) and relative survival based on tumour spread and site among CRC patients diagnosed between 1991 and 2015 in Finland. We conducted a population-based registry study among 59 465 CRC patients identified from the Finnish Cancer Registry. The 5-year DSS for all CRC patients was 56.7% [95% confidence interval (CI) 56.3-57.1%] for 1991 through 2015. Tumour site-specific survival has improved for the period 2006-2015 versus 1991-2005 for right-sided colon cancer from 54.8% (95% CI 53.8-55.8%) to 59.9% (95% CI 58.7-61.1%), for left-sided colon cancer from 54.1% (95% CI 52.9-55.3%) to 61.0% (95% CI 59.8-62.2%) and for rectal cancer from 53.6% (95% CI 52.2-55.0%) to 62.3% (95% CI 61.3-63.3%). The 5-year relative survival for the period 2006 through 2015 was 93.6% for localised disease (stage I); 84.2% for locally advanced tumour invading adjacent structures (stage II); 68.2% for regional disease with regional lymph node metastases (stage III); and 14.0% for metastatic disease (stage IV). This study confirms that survival for CRC has improved in recent decades in Finland, mirroring observations from other Western countries. However, the classification of tumour spread within the Finnish Cancer Registry differs slightly from the TNM classification, thereby limiting the generalisability of these results.